Pulse Biosciences, Inc. (NASDAQ:PLSE - Get Free Report)'s stock price passed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $18.08 and traded as low as $14.03. Pulse Biosciences shares last traded at $15.57, with a volume of 196,503 shares trading hands.
Wall Street Analysts Forecast Growth
Separately, StockNews.com raised shares of Pulse Biosciences to a "sell" rating in a report on Monday, March 31st.
Check Out Our Latest Stock Report on Pulse Biosciences
Pulse Biosciences Price Performance
The company has a 50-day simple moving average of $17.68 and a 200-day simple moving average of $17.92.
Institutional Trading of Pulse Biosciences
Hedge funds and other institutional investors have recently modified their holdings of the stock. Tower Research Capital LLC TRC increased its stake in shares of Pulse Biosciences by 98.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,692 shares of the company's stock valued at $29,000 after buying an additional 838 shares during the period. Charles Schwab Investment Management Inc. lifted its position in Pulse Biosciences by 0.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 149,206 shares of the company's stock valued at $2,598,000 after purchasing an additional 1,092 shares during the period. Rhumbline Advisers boosted its stake in shares of Pulse Biosciences by 6.3% in the 1st quarter. Rhumbline Advisers now owns 27,375 shares of the company's stock valued at $440,000 after purchasing an additional 1,614 shares during the last quarter. Farther Finance Advisors LLC grew its position in shares of Pulse Biosciences by 24.6% during the 1st quarter. Farther Finance Advisors LLC now owns 8,998 shares of the company's stock worth $143,000 after buying an additional 1,778 shares during the period. Finally, Wells Fargo & Company MN raised its stake in shares of Pulse Biosciences by 27.1% during the fourth quarter. Wells Fargo & Company MN now owns 11,315 shares of the company's stock worth $197,000 after buying an additional 2,416 shares during the last quarter. Institutional investors and hedge funds own 76.95% of the company's stock.
Pulse Biosciences Company Profile
(
Get Free Report)
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
See Also
Before you consider Pulse Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pulse Biosciences wasn't on the list.
While Pulse Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
